QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing
- New Barcelona site to help drive global expansion of QIAstat-Dx as QIAGEN expands local presence with multi-year investment
- Site in Esplugues de Llobregat to serve as an innovation hub for QIAstat-Dx, supporting the development of infectious disease tests and precision medicine applications
BARCELONA, Spain & VENLO, the Netherlands–(BUSINESS WIRE)–
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to move its QIAstat-Dx operations within the Barcelona area to a new site in Esplugues de Llobregat as part of a multi-year investment to strengthen this business.
Set to open in early 2026, the new site will cover the entire value chain for the QIAstat-Dx system, which is used for syndromic testing to identify the cause of an illness – especially in the areas of respiratory, gastrointestinal and meningitis / encephalitis conditions.
QIAstat-Dx is also being developed for use in precision medicine, in particular to support the expansion of recent partnerships announced with Eli Lilly and AstraZeneca. In precision medicine applications, QIAstat‑Dx for instance enables specialty care providers to perform genotyping whilst patients undergo routine clinical examination, thus enabling fast decision-making for potential suitability for certain genomically targeted medicines.
The new site builds on the long-standing presence of QIAGEN in the Barcelona area. Teams at the site will include Research & Development, Manufacturing, Sales, Marketing, Quality Assurance and Regulatory Affairs. In addition, it will serve as a center of excellence for R&D in microfluidics, as well as system and assay development.
“QIAstat-Dx demonstrated its value during the COVID-19 pandemic, supporting healthcare providers with rapid syndromic testing and crucial information when time mattered most,” said Thierry Bernard, CEO of QIAGEN. “Now we are building on this success by expanding the QIAstat-Dx pipeline to address a broader spectrum of healthcare needs. This means both expanding the range of pathogens for infectious disease testing as well as developing solutions for other disease areas and precision medicine applications.”
Barcelona provides an ideal location for this expansion, combining access to scientific talent with a robust ecosystem that includes universities, research institutions, start-ups, and well established pharma and life science companies.
QIAGEN can also build on the local expertise in the QIAstat-Dx technology, which was originally developed by a start-up from Barcelona and acquired by QIAGEN in 2018.
The Esplugues de Llobregrat site will enable QIAGEN to advance diagnostic capabilities in infectious diseases and beyond, helping to meet the growing demand for rapid diagnostics in diverse healthcare settings, from hospitals and clinics to decentralized testing points. The site will span 8,000 square meters and include offices, manufacturing lines, clean rooms, laboratories and logistics areas. The base building of the new facility has received LEED Platinum Certification, the highest standard in energy-efficient and environmentally responsible building design. The fit-out of the new facility will also meet this high standard and will be equipped with digitalized production lines.
The QIAstat-Dx system, designed for laboratory use, employs cost-efficient, single-use cartridges with built-in sample processing and on-board reagents. Utilizing multiplex real-time PCR, it detects and differentiates between multiple genetic targets, with results in about an hour. QIAstat-Dx also provides easy‑to‑view cycle threshold (Ct) values and amplification curves, offering additional insights not available with end-point PCR or other techniques.
Four QIAstat-Dx panels have been cleared by the U.S. Food and Drug Administration (FDA), including panels for pathogens causing respiratory and gastrointestinal infections, meningitis and encephalitis. In the European Union and other countries that accept the marking, two panels for detecting respiratory and gastrointestinal infections have received CE-marking under the new In-Vitro Diagnostic Medical Devices Regulation (IVDR).
The system already has a strong footprint in infectious disease testing and will be further strengthened by accelerating innovations and expanding the testing menu to a broader range of pathogens, such as blood culture identification and complicated urinary tract infections
QIAGEN has already signed three partnerships with pharma companies including Eli Lilly and AstraZeneca to expand QIAstat‑Dx beyond infectious diseases. The new facilities will support this expansion into other disease areas such as neurodegenerative, metabolic, inflammatory and other genetically driven chronic diseases.
For more information on QIAstat-Dx visit https://www.qiagen.com/de-us/applications/syndromic-testing.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2024, QIAGEN employed more than 5,800 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.
Category: Corporate
View source version on businesswire.com: https://www.businesswire.com/news/home/20241128928344/en/
QIAGEN:
Investor Relations
John Gilardi, +49 2103 29 11711
Domenica Martorana, +49 2103 29 11244
e-mail: [email protected]
Public Relations
Thomas Theuringer, +49 2103 29 11826
Lisa Specht, +49 2103 29 14181
e-mail: [email protected]
KEYWORDS: Germany Europe Spain Netherlands
INDUSTRY KEYWORDS: Science Biotechnology Research General Health Health Medical Devices Infectious Diseases Health Technology
MEDIA:
| Logo |
 |